7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal
Key Takeaways
- Coagulation factor deficiencies, primary hypercoagulable states, antiphospholipid antibody syndrome and undifferentiated thrombotic disorders are the enumerated topics.
- A mixing study that corrects indicates factor deficiency, whereas failure to correct indicates an inhibitor such as a lupus anticoagulant or an acquired factor antibody.
- Antiphospholipid syndrome requires a persistently positive antibody on two occasions at least twelve weeks apart together with thrombosis or pregnancy morbidity.
- Warfarin rather than a direct oral anticoagulant is indicated in triple-positive antiphospholipid syndrome because of higher recurrent thrombosis rates with direct agents.
- Four-factor prothrombin complex concentrate with vitamin K reverses warfarin in major bleeding, while idarucizumab reverses dabigatran and andexanet alfa reverses factor Xa inhibitors.
Last updated: August 2026
1. Coagulation Cascades & Mixing Studies
Interpreting 1:1 Mixing Studies
A mixing study is performed when a patient has an unexplained prolongation of the activated partial thromboplastin time (aPTT) or prothrombin time (PT).
- Patient plasma is mixed 1:1 with normal pooled plasma (which contains 100% activity of all clotting factors):
- Correction of aPTT (Immediate & Incubated): The added normal plasma supplies the missing clotting factor. This confirms a Factor Deficiency (e.g., Factor VIII [Hemophilia A], Factor IX [Hemophilia B], Factor XI, or Factor XII deficiency).
- Failure to Correct (or correction immediately that prolongs after 2-hour 37°C incubation): Indicates the presence of a circulating inhibitor:
- Time/Temperature-Dependent Inhibitor: Acquired Factor VIII Inhibitor (autoantibody against FVIII; prolonged aPTT worsens after 2 hours at 37°C).
- Immediate Inhibitor (Non-time-dependent): Lupus Anticoagulant (Antiphospholipid antibody); does not correct immediately or after incubation. Confirmed with Dilute Russell Viper Venom Time (dRVVT) showing neutralization with excess phospholipids.
Inherited & Acquired Bleeding Coagulopathies
| Coagulopathy | Genetics / Etiology | Coagulation Profile | Clinical Manifestations | Definitive Treatment |
|---|---|---|---|---|
| Hemophilia A | X-linked recessive; Factor VIII deficiency | Isolated prolonged aPTT (corrects on 1:1 mix); normal PT/INR, normal platelets | Recurrent hemarthroses, target joint arthropathy, deep muscle hematomas | Recombinant/plasma-derived Factor VIII concentrate; Emicizumab (bispecific antibody bridging FIXa and FX) for prophylaxis; DDAVP for mild disease |
| Hemophilia B | X-linked recessive; Factor IX deficiency (Christmas disease) | Isolated prolonged aPTT (corrects on 1:1 mix); normal PT/INR | Identical clinical presentation to Hemophilia A | Recombinant/plasma-derived Factor IX concentrate (DDAVP is ineffective) |
| Von Willebrand Disease (vWD) | Autosomal dominant (Type 1 [70–80%, partial quantitative], Type 2 [qualitative]); Autosomal recessive (Type 3 [severe]) | Prolonged PFA-100 closure time, normal or prolonged aPTT (if FVIII binding reduced), normal PT/INR | Mucosal bleeding, menorrhagia, epistaxis, gingival hemorrhage, post-dental extraction bleeding | Desmopressin (DDAVP) for Type 1 (induces endothelial Weibel-Palade release); vWF/Factor VIII concentrates (Humate-P) for Type 2/3 or surgery; Tranexamic acid |
| Acquired Factor VIII Inhibitor | Acquired IgG autoantibody against FVIII (elderly, postpartum, autoimmune) | Isolated prolonged aPTT that DOES NOT correct on incubated 1:1 mix; low FVIII activity | Severe spontaneous soft tissue bleeding, extensive ecchymoses, hematomas (hemarthroses rare) | Bypassing agents: Recombinant Factor VIIa (rFVIIa) or Activated Prothrombin Complex Concentrate (FEIBA); + Immunosuppression (Prednisone + Cyclophosphamide / Rituximab) |
| Disseminated Intravascular Coagulation (DIC) | Massive systemic tissue factor release (sepsis, trauma, obstetric emergencies, APL) | Elevated PT/INR, elevated aPTT, low Fibrinogen (< 150 mg/dL), elevated D-dimer, low platelets | Diffuse oozing from IV sites/wounds, petechiae, concurrent arterial/venous microthrombosis | Treat underlying cause; Cryoprecipitate (to maintain fibrinogen > 150–200 mg/dL), Platelets (> 50k), Fresh Frozen Plasma (for active severe bleeding) |
2. Thrombophilia & Hypercoagulable States
Inherited Thrombophilias
- Factor V Leiden (FVL) Mutation: Point mutation (G1691A) replacing arginine with glutamine at position 506 in the Factor V molecule, destroying the cleavage site for Activated Protein C (Activated Protein C Resistance [APCR]). Most common inherited thrombophilia in Caucasian populations (3–8% heterozygote prevalence). Heterozygotes have 3–5x increased risk of VTE; homozygotes have 50–80x increased risk.
- Prothrombin G20210A Mutation: Gain-of-function mutation in the 3'-untranslated region of the prothrombin gene leading to elevated plasma prothrombin (Factor II) levels and 2–3x increased VTE risk.
- Protein C and Protein S Deficiencies: Autosomal dominant deficiencies of Vitamin K-dependent natural anticoagulants. Predisposes to venous thromboembolism, purpura fulminans in neonates, and warfarin-induced skin necrosis during unbridged warfarin initiation.
- Antithrombin (ATIII) Deficiency: Inherited or acquired (nephrotic syndrome with urinary ATIII wasting, cirrhosis, ECMO). Causes heparin resistance (inability to achieve therapeutic aPTT despite high doses of unfractionated heparin, because heparin requires antithrombin to exert its anticoagulant effect).
Acquired Thrombophilia: Antiphospholipid Syndrome (APLS)
- Diagnostic Criteria (Sapporo / Sydney Criteria): Requires at least 1 clinical criterion AND at least 1 laboratory criterion documented on ≥ 2 occasions at least 12 weeks apart:
- Clinical Criteria:
- Vascular thrombosis: ≥ 1 episode of venous, arterial, or small-vessel thrombosis.
- Pregnancy morbidity: ≥ 1 unexplained fetal death ≥ 10 weeks gestation, ≥ 3 consecutive unexplained spontaneous abortions < 10 weeks gestation, or ≥ 1 premature birth < 34 weeks due to severe preeclampsia/eclampsia or placental insufficiency.
- Laboratory Criteria (Positive ≥ 12 weeks apart):
- Lupus Anticoagulant (LA) detected via functional clotting assays (dRVVT).
- Anticardiolipin Antibody (aCL) IgG or IgM (> 40 GPL/MPL or > 99th percentile).
- Anti-$\beta_2$-Glycoprotein I Antibody IgG or IgM (> 99th percentile).
- Clinical Criteria:
- Anticoagulation Standard of Care:
- For thrombotic APLS, lifelong anticoagulation with Warfarin (target INR 2.0–3.0) is the standard of care.
- Direct Oral Anticoagulants (DOACs) are CONTRAINDICATED in thrombotic APLS (especially "triple-positive" patients) due to significantly higher rates of recurrent arterial thromboembolic events (stroke, myocardial infarction) compared to Warfarin (demonstrated in the randomized TRAPS and RAPID trials).
3. Anticoagulant Reversal Strategies
| Anticoagulant Agent | Mechanism of Action | Monitoring Assay | Specific Reversal Agent / Management |
|---|---|---|---|
| Warfarin | Inhibits Vitamin K Epoxide Reductase (VKORC1); depletes active Factors II, VII, IX, X, Protein C, S | PT / INR | Life-Threatening Bleeding: 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) weight-based (25–50 units/kg based on baseline INR) PLUS IV Vitamin K1 (Phytonadione 10 mg) slow infusion.<br/>Urgent reversal without bleeding: Oral Vitamin K 2.5–5.0 mg. |
| Dabigatran (Pradaxa) | Direct competitive Thrombin (Factor IIa) inhibitor | Thrombin Time (TT), Dilute Thrombin Time, aPTT | Idarucizumab (Praxbind) 5.0 g IV (two 2.5 g vials administered in rapid succession). Binds dabigatran with 350x higher affinity than thrombin. |
| Apixaban (Eliquis) / Rivaroxaban (Xarelto) | Direct competitive Factor Xa inhibitors | Anti-Factor Xa activity (calibrated) | Andexanet alfa (Andexxa): Recombinant modified decoy Factor Xa protein. High- or low-dose IV bolus followed by 2-hour infusion.<br/>Alternative if unavailable: 4-Factor PCC (50 units/kg IV). |
| Unfractionated Heparin (UFH) | Binds Antithrombin III, potentiates inhibition of thrombin and Factor Xa | aPTT (target 50–70s), Anti-Xa | Protamine Sulfate: 1.0 mg IV per 100 units of UFH administered over preceding 2–3 hours (max dose 50 mg to avoid intrinsic anticoagulant toxicity). |
| Low-Molecular-Weight Heparin (Enoxaparin) | Primarily inhibits Factor Xa via ATIII | Anti-Factor Xa level | Protamine Sulfate: 1.0 mg per 1.0 mg of Enoxaparin administered within preceding 8 hours (partially neutralizes ~60–75% of anti-Xa activity). |
Test Your Knowledge
A 32-year-old woman with a history of two unprovoked deep vein thromboses and two consecutive second-trimester pregnancy losses presents for long-term anticoagulation counseling. Laboratory testing confirms the persistent presence of Lupus Anticoagulant, high-titer anticardiolipin IgG antibodies, and high-titer anti-beta-2-glycoprotein I IgG antibodies on two occasions 14 weeks apart (triple-positive Antiphospholipid Syndrome). What is the recommended long-term antithrombotic management for secondary stroke and VTE prevention?
A
B
C
D